· AIM: To investigate the possibility of FLK-1 as a therapeutic agent for choroidal neovascularization (CNV) in mouse by FLK1 monoclonal antibody.· METHODS: CNV was induced in C57BL/6 mouse eyes by krypton laser photocoagulation. Preoperatively and on the 3rd, 6th and 9th day after photocoagulation, the animals were intraperitoneally injected with 500μg FLK1 monoclonal antibody. Choroidal fluorescein angiography and histopathological examination were used to assess the development of experimental CNV quantitatively 10 days after laser treatment.· RESULTS: Laser-induced CNV developed in all lesions on the 10th day after the operation. The development of CNV was significantly inhibited in experimental group, indicated by choroidal fluorescein angiography and histopathological examination (P＜0.001).· CONCLUSION: Our findings suggest that FLK-1 may be a promising agent for anti-angiogenesis therapy for CNV.%目的:探讨FLK-1单克隆抗体对小鼠脉络膜新生血管(choroidal neovascularization,CNV)的治疗作用.方法:采用激光击射的方法诱导成年C57BL/6小鼠CNV模型,术前及术后3,6,9d利用腹腔注射的方法给与实验组小鼠FLK-1单克隆抗体500 μg,激光术后10d处死小鼠,行脉络膜灌流铺片及组织病理学检查观察CNV的发展,定量评价FLK-1单克隆抗体对于实验性CNV的治疗作用.结果:术后10d所有激光光斑均发展为实验性CNV,脉络膜灌流铺片及组织病理学检查结果一致表明实验组小鼠CNV的发展受到明显抑制(P＜0.001).结论:FLK-1单克隆抗体可以抑制实验性CNV的发展,提示拮抗FLK-1可能成为治疗CNV有效的生物学方法之一.
展开▼
